Conclusion
In the present study, we have investigated the significance of four SLC polymorphisms on the survival of North Indian lung carcinoma patients undergoing platinum-based chemotherapy regimens. Briefly, we used genotyping analysis to see if SLC polymorphism causes differences in patient clinical outcomes. Our findings imply that SLC polymorphisms are essential in regulating SLC gene expression, altering the transporter activity, and affecting overall survival in lung cancer patients. To the best of our knowledge, this is the first study to evaluate the role of SLC polymorphism in North Indian lung cancer patients.According to our findings, genotyping for the SLCpolymorphism could be a valuable tool for predicting which lung cancer patients will benefit the most from platinum-based chemotherapy.However, a review of previous papers reveals a plethora of contradictory findings of the activity of these transporters. Nonetheless, more research into the role of SLC polymorphisms is needed before a meaningful conclusion can be reached.
When adopting this technique in the clinic, significant caution should be exercised to better and personalize therapeutic choices to predict prognosis and therapy outcomes. Our study evaluates the survival differences in lung cancer patients with SLC polymorphisms. Surprisingly, our findings demonstrate a link between SLCpolymorphism and a lower risk of toxicity in north Indian lung cancer patients.It is well understood that individual toxicities are determined by the platinum-based chemotherapy regimen used. In the future, further studies should be explored to analyze the impact of these SLC polymorphisms on the activity of SLC transporter in order to identify the involvement of a specific polymorphism in the pharmacokinetics, pharmacological activity, and toxicity of chemotherapeutic agents. Such insights could lead to pharmacogenetically enhanced and individualized drug dosing, correspondingto pharmacokinetic discrepancies in chemotherapeutic drugs between individuals.